摘要
目的:探讨舒利迭、倍择瑞吸入治疗哮喘慢阻肺重叠综合征(ACOS)患者的疗效。方法:选取103例ACOS患者为研究对象,根据治疗方案不同分为舒利迭组(n=52)和倍择瑞组(n=51)。舒利迭组患者给予舒利迭治疗;倍择瑞组患者给予倍择瑞治疗,疗程均为90 d。比较两组患者临床疗效、病情控制情况[慢阻肺评分(CAT评分)、哮喘控制评分(ACT评分)]、肺功能改善情况[第1秒用力呼气容积(FEV1)、用力肺活量(FVC)、吸气分数(IC/TLC)]、T淋巴细胞免疫变化[辅助性T细胞17(Th17)、调节性T细胞(Treg)水平]、血清指标水平[白细胞介素17(IL-17)及嗜酸性粒细胞计数(EOS)]、不良反应发生情况及疾病进展情况。结果:倍择瑞组患者临床疗效优于舒利迭组(P<0.05)。治疗后,两组患者CAT评分及FeNO、Th17、EOS、IL-17水平均降低(P<0.05),且倍择瑞组低于舒利迭组(P<0.05);ACT评分及FEV1、FVC、IC/TLC、Treg水平均升高,且倍择瑞组高于舒利迭组(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05);倍择瑞组患者急性加重率、急诊就诊率低于舒利迭组(P<0.05)。结论:倍择瑞可改善ACOS患者肺功能及免疫功能,且安全性好,值得推广应用。
Objective:To explore the efficacy of Seretide and Breztri Aerosphere inhalation in the treatment of patients with asthma-chronic obstructive pulmonary disease overlap syndrome(ACOS).Methods:103 patients with ACOS were selected as study subjects,and were divided into Seretide group(n=52)and Breztri Aerosphere group(n=51)according to different treatment regimens.Patients in Seretide group were treated with Seretide,while patients in the Breztri Aerosphere group received Breztri Aerosphere treatment.The course of treatment was 90 days.The clinical efficacy,disease control status[chronic obstructive pulmonary disease score(CAT),asthma control score(ACT)],improvement of lung function[forced expiratory volume in one second(FEV1),forced vital capacity(FVC),inspiratory fraction(IC/TLC)],immune changes in T lymphocytes[helper T cell 17(Th17),regulatory T cell(Treg)],serum indicators[interleukin 17(IL-17),eosinophil count(EOS)],occurrence of adverse reactions and disease progression were compared between the two groups of patients.Results:The clinical efficacy in Breztri Aerosphere group was better than that in Seretide group(P<0.05).After treatment,the CAT score and levels of FeNO,Th17,EOS and IL-17 in the two groups of patients were decreased(P<0.05),and Breztri Aerosphere group showed lower score and levels compared to Seretide group(P<0.05).The ACT score and levels of FEV1,FVC,IC/TLC and Treg were increased in both groups,and Breztri Aerosphere group had higher score and levels than those in Seretide group(P<0.05).There was no statistical difference in the incidence of adverse reactions between the two groups(P>0.05).The acute exacerbation rate and emergency visit rate in Breztri Aerosphere group were lower than those in Seretide group(P<0.05).Conclusion:Breztri Aerosphere can improve the pulmonary function and immune function in patients with ACOS,and has high safety,which is worth promoting and applying.
作者
卿红
万丹
QING Hong;WAN Dan(Department of Pharmacy,the General Hospital of Western Theater Command,Chengdu 610083,Sichuan,China)
出处
《川北医学院学报》
2026年第1期113-117,共5页
Journal of North Sichuan Medical College
关键词
布地格福
沙美特罗替卡松
哮喘慢阻肺重叠综合征
肺功能
Budesonide,glycopyrronium bromide and formoterol fumarate
Salmeterol fluticasone
Asthma-chronic obstructive pulmonary disease overlap syndrome
Pulmonary function
